No Data
Express News | Mirum’s Livmarli Now Approved for Pfic in Patients 12 Months and Older
The 9.9% Return This Week Takes Mirum Pharmaceuticals' (NASDAQ:MIRM) Shareholders Five-year Gains to 183%
JMP Securities Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $69
JMP Securities analyst Jonathan Wolleben maintains $Mirum Pharmaceuticals(MIRM.US)$ with a buy rating, and maintains the target price at $69.According to TipRanks data, the analyst has a success
Mirum Pharmaceuticals (MIRM) Gets a Buy From JMP Securities
Mirum Pharmaceuticals (NASDAQ:MIRM) Delivers Shareholders Solid 23% CAGR Over 5 Years, Surging 11% in the Last Week Alone
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)